The European CGM market comprises the CGM system segment and the CGM sensor segment. The business model for CGM is similar to traditional blood glucose meters, where the CGM system is the base equipment and the majority of sales are made from the disposable sensor component, which is replaced every three to seven days depending on the manufacturer. The CGM market is still considered to be in its infancy, but the disposable sensors will be the most important revenue generator as the technology gains further acceptance.
Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings.
The CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for three to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.
'
TABLE OF CONTENTS I
LIST OF FIGURES IV
LIST OF CHARTS VI
EXECUTIVE SUMMARY 1
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
MARKETS INCLUDED 9
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
1.1 RESEARCH SCOPE 11
1.2 IDATA’S 9-STEP METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 13
Step 3: Preparation for Interviews & Questionnaire Design 14
Step 4: Performing Primary Research 15
Step 5: Research Analysis: Establishing Baseline Estimates 17
Step 6: Market Forecast and Analysis 18
Step 7: Identify Strategic Opportunities 20
Step 8: Final Review and Market Release 21
Step 9: Customer Feedback and Market Monitoring 22
DISEASE OVERVIEW 23
2.1 INTRODUCTION 23
2.1.1 Types of Diabetes 23
2.1.2 Diabetes Complications 25
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 27
2.1.4 Signs and Symptoms 28
2.1.5 Diabetes Monitoring 29
2.1.6 Treatment 31
2.1.7 Drug Delivery Systems 33
COUNTRY PROFILES 35
3.1 INTRODUCTION 35
3.1.1.1 Population 35
3.1.1.2 GDP Per Capita 35
3.1.1.3 Units 35
3.2 GERMANY 36
3.3 FRANCE 37
3.4 UNITED KINGDOM 38
3.5 ITALY 39
3.6 SPAIN 40
3.7 BENELUX 41
3.8 SCANDINAVIA 42
3.9 AUSTRIA 43
3.10 SWITZERLAND 44
3.11 PORTUGAL 45
CONTINUOUS GLUCOSE MONITORING MARKET 46
4.1 INTRODUCTION 46
4.2 MARKET OVERVIEW 48
4.3 MARKET ANALYSIS AND FORECAST 52
4.3.1 Total CGM Market 52
4.3.2 CGM System Market 54
4.3.3 CGM Sensor Market 61
4.3.4 Emerging Markets: Non-Invasive CGM 68
4.4 DRIVERS AND LIMITERS 70
4.4.1 Market Drivers 70
4.4.2 Market Limiters 71
4.5 COMPETITIVE MARKET SHARE ANALYSIS 73
ABBREVIATIONS 76
Chart 1 1: Diabetes Diagnosis, Treatment and Drug Delivery, Europe, 2012 – 2022 3
Chart 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Market Overview, Europe, 2012 & 2022 3
Chart 3 1: Country Profile, Germany, 2015 36
Chart 3 2: Country Profile, France, 2015 37
Chart 3 3: Country Profile, United Kingdom, 2015 38
Chart 3 4: Country Profile, Italy, 2015 39
Chart 3 5: Country Profile, Spain, 2015 40
Chart 3 6: Country Profile, Benelux, 2015 41
Chart 3 7: Country Profile, Scandinavia, 2015 42
Chart 3 8: Country Profile, Austria, 2015 43
Chart 3 9: Country Profile, Switzerland, 2015 44
Chart 3 10: Country Profile, Portugal, 2015 45
Chart 4 1: Total CGM Market by Segment, Europe, 2015 50
Chart 4 2: Total CGM Market Breakdown, Europe, 2022 51
Chart 4 3: Total CGM Market Breakdown, Europe, 2022 51
Chart 4 4: Total CGM System Market, Europe, 2012 – 2022 (€M) 53
Chart 4 5: CGM System Market, Europe, 2012 – 2022 55
Chart 4 6: CGM Sensor Market, Europe, 2012 – 2022 62
Chart 4 7: Leading Competitors, CGM Market, Europe, 2015 75
Figure 1 1: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (1 of 2) 4
Figure 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (2 of 2) 4
Figure 1 3: Companies Researched in this Report, Europe, 2015 5
Figure 1 4: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (1 of 2) 6
Figure 1 5: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (2 of 2) 7
Figure 1 6: Recent Events in the Diabetes Diagnosis, Treatment and Drug Delivery Market, Europe, 2012 – 2016 8
Figure 2 1: Major Types of Diabetes and Related Pathologies, Europe, 2015 24
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, Europe, 2015 28
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, Europe, 2015 29
Figure 4 1: Total CGM Market by Segment, Europe, 2012 – 2022 (€M) 49
Figure 4 2: Total CGM Market by Segment, Europe, 2012 – 2022 (US$M) 49
Figure 4 3: Total CGM Market, Europe, 2012 – 2022 (€ and US$) 52
Figure 4 4: CGM System Market, Europe, 2012 – 2022 (€ and US$) 54
Figure 4 5: Units Sold by Country, CGM System Market, Europe, 2012 – 2022 56
Figure 4 6: Average Selling Price by Country, CGM System Market, Europe, 2012 – 2022 (€) 57
Figure 4 7: Average Selling Price by Country, CGM System Market, Europe, 2012 – 2022 (US$) 58
Figure 4 8: Market Value by Country, CGM System Market, Europe, 2012 – 2022 (€M) 59
Figure 4 9: Market Value by Country, CGM System Market, Europe, 2012 – 2022 (US$M) 60
Figure 4 10: CGM Sensor Market, Europe, 2012 – 2022 (€ and US$) 61
Figure 4 11: Units Sold by Country, CGM Sensor Market, Europe, 2012 – 2022 63
Figure 4 12: Average Selling Price by Country, CGM Sensor Market, Europe, 2012 – 2022 (€) 64
Figure 4 13: Average Selling Price by Country, CGM Sensor Market, Europe, 2012 – 2022 (US$) 65
Figure 4 14: Market Value by Country, CGM Sensor Market, Europe, 2012 – 2022 (€M) 66
Figure 4 15: Market Value by Country, CGM Sensor Market, Europe, 2012 – 2022 (US$M) 67
Figure 4 16: Drivers and Limiters, CGM Market, Europe, 2015 72
Figure 4 17: Leading Competitors, CGM Market, Europe, 2015 74
Novo Nordisk
Sanofi
Roche
Johnson & Johnson
Eli Lilly
Abbott
Ascensia
Becton Dickinson
Medtronic
Menarini
DexCom
Ypsomed
Insulet
Artsana
B. Braun
Terumo
Others include: Abbott, AgaMatrix, Artsana, Apollo, BBI Healthcare, B. Braun, Berger, Beurer, Boehringer Ingelheim, Cellnovo, Codan, Comfort Point, Dario Health, Elektronika, Entra Health Systems, GlucoRx, GlucoZen, Infopia, Medtronic, MED TRUST, Medisana, Menarini, Merck Serono, MSP bodmann, Neon Diagnostics, NordicInfu Care, Novalab Ibérica, Novico, Owen Mumford, Pentaferte, Roche, Sanofi, SD BIOSENSOR, SFM Medical, Smiths Medical, Spirit Healthcare, Sooil, Trividia Health, Ypsomed, etc.
